Sanara MedTech Inc.

Item 5.07. Submission of Matters to a Vote of Security Holders Results of Special Meeting On September 30, 2026, Sanara MedTech Inc., a Texas corporation ( “Sanara”), held a special meeting of shareholders (the “Special Meeting”) to vote on the proposals described in Sanara’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on September 4, 2026 (the “Proxy Statement”). As of the close of business on September 1, 2026, the record date for the Special Meeting (the “Record Date”), there were 9,188,035 shares of Sanara’s common stock, par value $0.001 per share (the “Common Stock”), outstanding, each of which was entitled to one vote on each proposal at the Special Meeting. At the Special Meeting, a total of 6,411,427 shares of Common Stock, representing approximately 69.78% of the outstanding shares of Common Stock, were present in person or represented by proxy, constituting a quorum to conduct business. At the Special Meeting, Sanara’s shareholders voted on the following matters: A proposal to approve and adopt the Agreement and Plan of Merger, dated as of July 29, 2026 (as it may be amended, supplemented, waived or otherwise modified in accordance with its terms, the “Merger Agreement”), by and among Sanara, MiMedx Group, Inc., a Florida corporation (“MiMedx”) and Mustang Merger Sub, Inc., a Texas corporation and a wholly-owned subsidiary of MiMedx (“Merger Sub”), pursuant to which, among other things, Merger Sub will merge with and into Sanara, with Sanara surviving as a wholly-owned subsidiary of MiMedx (the “Merger”), and approve the consummation of the transactions contemplated by the Merger Agreement, including the Merger (“Proposal No. 1”); ───────────────────────────────────────────────────────────────────────────────────────────────────── A proposal to approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to Sanara’s named executive officers that is based on or otherwise relates to the Merger (“Proposal No. 2”); and ──────────────────────────────────────────────────────────────────────────────────────────── A proposal to approve one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes cast at the Special Meeting to approve Proposal No. 1 (“Proposal No. 3”). The final voting results for each proposal are described below. Proposal No. 3 was not submitted to Sanara’s shareholders for approval at the Special Meeting because there were sufficient votes to approve Proposal No. 1. For more information on each of these proposals, see the Proxy Statement. Proposal No. 1. Sanara’s shareholders approved Proposal No. 1. The votes cast on Proposal No. 1 were as follows: For Against Abstain Broker Non-Votes ───────────────────────────────────────────────────────────── 6,372,989 1,944 36,494 N/A Proposal No. 2. Sanara’s shareholders approved Proposal No. 2. The votes cast on Proposal No. 2 were as follows: For Against Abstain Broker Non-Votes ───────────────────────────────────────────────────────────── 5,841,470 75,247 494,710 N/A

Item 8.01. Other Events Update on Regulatory Approvals As previously disclosed, MiMedx and Sanara filed their respective notification and report forms pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”) on August 12, 2026. In order to provide the Federal Trade Commission with additional time for review, on September 11, 2026, MiMedx, in consultation with Sanara, voluntarily withdrew its notification and report form pursuant to 16 C.F.R. § 803.12 and refiled its notification and report form on September 15, 2026, commencing a new 30-calendar-day waiting period under the HSR Act. Unless extended or earlier terminated, the waiting period under the HSR Act will expire at 11:59 p.m. Eastern Time on October 15, 2026. The consummation of the Merger remains subject to the satisfaction or waiver of the other conditions set forth in the Merger Agreement.